Paul Matteis
Stock Analyst at Stifel Nicolaus
(4.82)
# 469
Out of 4,609 analysts
720
Total ratings
53%
Success rate
17.4%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintained: Hold | $25 | $28.80 | -13.19% | 51 | Aug 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Hold | $466 → $500 | $484.83 | +3.13% | 42 | Aug 4, 2026 | |
| BIIB Biogen | Maintained: Buy | $214 → $242 | $206.63 | +17.12% | 52 | Aug 2, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Hold | $86 → $68 | $54.19 | +25.48% | 33 | Aug 2, 2026 | |
| ALNY Alnylam Pharmaceuticals | Rated: Buy | $444 → $318 | $228.72 | +39.03% | 48 | Jul 31, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $188 → $215 | $161.50 | +33.13% | 55 | Jul 31, 2026 | |
| DYN Dyne Therapeutics | Maintained: Buy | $36 → $37 | $26.17 | +41.38% | 27 | Jul 31, 2026 | |
| ALKS Alkermes | Maintained: Buy | $63 | $49.61 | +26.99% | 59 | Jul 25, 2026 | |
| DFTX Definium Therapeutics | Rated: Buy | $30 → $60 | $44.39 | +35.17% | 5 | Jul 8, 2026 | |
| CMPS COMPASS Pathways | Rated: Buy | $14 → $21 | $13.58 | +54.64% | 7 | Jul 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $46 | $35.98 | +27.85% | 24 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $0.297 | +236.70% | 8 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 | $4.45 | +282.02% | 9 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $71 | $44.24 | +60.49% | 26 | Jun 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $133 | $110.71 | +20.13% | 12 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $22.34 | +34.29% | 2 | Jun 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $36 | $12.92 | +178.64% | 4 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $14.01 | +78.44% | 3 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 | $47.34 | +16.18% | 4 | May 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $68 | $59.91 | +13.50% | 44 | May 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $1.61 | +86.34% | 10 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 | $42.44 | +31.95% | 10 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $89 → $86 | $64.30 | +33.75% | 27 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 → $28 | $15.27 | +83.37% | 10 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.98 | +506.06% | 17 | Apr 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $33 | $28.03 | +17.73% | 10 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $41 | $24.42 | +67.90% | 28 | Mar 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $40 | $45.03 | -11.17% | 3 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 | $29.13 | +9.85% | 10 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.49 | - | 12 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.24 | +346.43% | 9 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.68 | n/a | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $12.47 | n/a | 11 | Jun 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $5.93 | n/a | 13 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $20 | $78.91 | n/a | 4 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.000001 | n/a | 1 | Aug 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $20 | $0.0001 | n/a | 4 | Mar 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.29 | n/a | 1 | Nov 23, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.60 | n/a | 4 | Jun 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $16.90 | n/a | 5 | Jun 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $0.0003 | n/a | 3 | May 19, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $14 → $7 | $0.9143 | n/a | 2 | May 6, 2016 |
ACADIA Pharmaceuticals
Aug 5, 2026
Maintained: Hold
Price Target: $25
Current: $28.80
Upside: -13.19%
Vertex Pharmaceuticals
Aug 4, 2026
Maintained: Hold
Price Target: $466 → $500
Current: $484.83
Upside: +3.13%
Biogen
Aug 2, 2026
Maintained: Buy
Price Target: $214 → $242
Current: $206.63
Upside: +17.12%
Ionis Pharmaceuticals
Aug 2, 2026
Maintained: Hold
Price Target: $86 → $68
Current: $54.19
Upside: +25.48%
Alnylam Pharmaceuticals
Jul 31, 2026
Rated: Buy
Price Target: $444 → $318
Current: $228.72
Upside: +39.03%
Neurocrine Biosciences
Jul 31, 2026
Maintained: Buy
Price Target: $188 → $215
Current: $161.50
Upside: +33.13%
Dyne Therapeutics
Jul 31, 2026
Maintained: Buy
Price Target: $36 → $37
Current: $26.17
Upside: +41.38%
Alkermes
Jul 25, 2026
Maintained: Buy
Price Target: $63
Current: $49.61
Upside: +26.99%
Definium Therapeutics
Jul 8, 2026
Rated: Buy
Price Target: $30 → $60
Current: $44.39
Upside: +35.17%
COMPASS Pathways
Jul 8, 2026
Rated: Buy
Price Target: $14 → $21
Current: $13.58
Upside: +54.64%
Jul 6, 2026
Maintained: Buy
Price Target: $46
Current: $35.98
Upside: +27.85%
Jul 6, 2026
Maintained: Hold
Price Target: $1
Current: $0.297
Upside: +236.70%
Jul 6, 2026
Maintained: Buy
Price Target: $17
Current: $4.45
Upside: +282.02%
Jun 21, 2026
Maintained: Buy
Price Target: $28 → $71
Current: $44.24
Upside: +60.49%
Jun 15, 2026
Reiterated: Buy
Price Target: $133
Current: $110.71
Upside: +20.13%
Jun 9, 2026
Reiterated: Buy
Price Target: $30
Current: $22.34
Upside: +34.29%
Jun 2, 2026
Reiterated: Buy
Price Target: $28 → $36
Current: $12.92
Upside: +178.64%
May 28, 2026
Maintained: Buy
Price Target: $25
Current: $14.01
Upside: +78.44%
May 25, 2026
Maintained: Buy
Price Target: $55
Current: $47.34
Upside: +16.18%
May 24, 2026
Maintained: Hold
Price Target: $68
Current: $59.91
Upside: +13.50%
May 12, 2026
Maintained: Hold
Price Target: $3
Current: $1.61
Upside: +86.34%
May 12, 2026
Maintained: Buy
Price Target: $56
Current: $42.44
Upside: +31.95%
May 8, 2026
Maintained: Buy
Price Target: $89 → $86
Current: $64.30
Upside: +33.75%
May 8, 2026
Maintained: Buy
Price Target: $29 → $28
Current: $15.27
Upside: +83.37%
Apr 4, 2026
Maintained: Buy
Price Target: $12
Current: $1.98
Upside: +506.06%
Apr 2, 2026
Maintained: Buy
Price Target: $33
Current: $28.03
Upside: +17.73%
Mar 29, 2026
Maintained: Buy
Price Target: $41
Current: $24.42
Upside: +67.90%
Mar 27, 2026
Reiterated: Buy
Price Target: $35 → $40
Current: $45.03
Upside: -11.17%
Mar 6, 2026
Reiterated: Buy
Price Target: $32
Current: $29.13
Upside: +9.85%
Dec 22, 2025
Rated: Hold
Price Target: n/a
Current: $1.49
Upside: -
Dec 16, 2025
Reiterated: Buy
Price Target: $10
Current: $2.24
Upside: +346.43%
Sep 19, 2024
Rated: Hold
Price Target: n/a
Current: $7.68
Upside: n/a
Jun 3, 2023
Maintained: Buy
Price Target: $5
Current: $12.47
Upside: n/a
May 12, 2022
Reiterated: Hold
Price Target: $3
Current: $5.93
Upside: n/a
Feb 28, 2022
Downgraded: Hold
Price Target: $11 → $20
Current: $78.91
Upside: n/a
Aug 16, 2017
Initiated Coverage: Buy
Price Target: $18
Current: $0.000001
Upside: n/a
Mar 10, 2017
Reiterated: Buy
Price Target: $14 → $20
Current: $0.0001
Upside: n/a
Nov 23, 2016
Reiterated: Buy
Price Target: n/a
Current: $2.29
Upside: n/a
Jun 20, 2016
Reiterated: Buy
Price Target: n/a
Current: $2.60
Upside: n/a
Jun 20, 2016
Reiterated: Buy
Price Target: $29
Current: $16.90
Upside: n/a
May 19, 2016
Maintained: Buy
Price Target: $11
Current: $0.0003
Upside: n/a
May 6, 2016
Reiterated: Hold
Price Target: $14 → $7
Current: $0.9143
Upside: n/a